SAN DIEGO -- Results from a small single-center study showed that treatment with a gene therapy involving the use of ...

In the groundbreaking study the researchers observed an annualised zero bleeding rate in all the five subjects enrolled with ...

VIVEbiotech, a leading lentiviral vector Contract Development and Manufacturing Organization (CDMO), today announced a growth equity investment from Ampersand Capital Partners (“Ampersand”), a private ...

Expression Therapeutics, Inc., has presented the results of a Phase 1 clinical trial for its novel lentiviral vector-based gene therapy ? ET3 ? for hemophilia A at the Annual Meeting of the American ...

BHUBANESWAR: In a significant medical breakthrough, India's first human gene therapy with a lentiviral vector for severe haemophilia-A has been found to be succ ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

India has successfully conducted its first in-human gene therapy for hemophilia A, with patients experiencing no bleeding ...

AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced the U.S. Food and Drug Administration (FDA) approved its Milan Cell and ...

Breakthrough in Delivering Chimeric Bait Receptors to Immune Cells Accelerates Development LONDON, UK / ACCESSWIRE / December ...

Among these sensors, we further focused on the spatiotemporal dynamics of Rab10 and Rab4 activity during sLTP. We found that postsynaptic stimulation leads to the persistent inactivation of Rab10 and ...